Advanced Search: Advanced/Metastatic

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201708148

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

201904214

IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations

201703178

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

202009082

A Phase 1b Clinical Trial of Cabozantinib and Abiraterone with Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

201901059

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

201903098

A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are 18F-DCFPyL prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naïve, and progressed on abiraterone (ARROW)

202006013

Phase II Trial of pTVG-HP DNA Vaccine with or without pTVG-AR DNA Vaccine and Pembrolizumab in Patients with Castration-Resistant, Metastatic Prostate Cancer

202006062

A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) - 10301

202007111

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer

202103170

SPLASH: Study Evaluating Metastatic Castrate Resistant ProstateCancer Treatment Using Lu-PNT2002 PSMA Therapy After Second-ilneHormonal Treatment